Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
mirabegron (myrbetriq) (1 trial)
suvorexant (belsomra) (1 trial)
Parkinson Disease (Phase 4)
Sleep Initiation and Maintenance Disorders (Phase 4)
Urinary Bladder, Overactive (Phase 4)
Trials (2 total)
Trial APIs (2 total)